243 related articles for article (PubMed ID: 21937681)
1. Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.
Ren M; Qin H; Ren R; Tidwell J; Cowell JK
Cancer Res; 2011 Dec; 71(23):7312-22. PubMed ID: 21937681
[TBL] [Abstract][Full Text] [Related]
2. Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome.
Chong Y; Liu Y; Lu S; Cai B; Qin H; Chang CS; Ren M; Cowell JK; Hu T
Int J Cancer; 2020 Apr; 146(8):2243-2254. PubMed ID: 31525277
[TBL] [Abstract][Full Text] [Related]
3. Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.
Ren M; Cowell JK
Blood; 2011 Jun; 117(25):6837-47. PubMed ID: 21527531
[TBL] [Abstract][Full Text] [Related]
4. miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the
Hu T; Chong Y; Lu S; Wang R; Qin H; Silva J; Kitamura E; Chang CS; Hawthorn L; Cowell JK
Cancer Res; 2018 Jul; 78(13):3522-3531. PubMed ID: 29735550
[TBL] [Abstract][Full Text] [Related]
5. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.
Ren M; Qin H; Ren R; Cowell JK
Leukemia; 2013 Jan; 27(1):32-40. PubMed ID: 22781593
[TBL] [Abstract][Full Text] [Related]
7. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.
Roumiantsev S; Krause DS; Neumann CA; Dimitri CA; Asiedu F; Cross NC; Van Etten RA
Cancer Cell; 2004 Mar; 5(3):287-98. PubMed ID: 15050920
[TBL] [Abstract][Full Text] [Related]
8. A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
[TBL] [Abstract][Full Text] [Related]
9. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
Fioretos T; Panagopoulos I; Lassen C; Swedin A; Billström R; Isaksson M; Strömbeck B; Olofsson T; Mitelman F; Johansson B
Genes Chromosomes Cancer; 2001 Dec; 32(4):302-10. PubMed ID: 11746971
[TBL] [Abstract][Full Text] [Related]
10. Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in Mice.
Hu T; Chong Y; Lu S; Qin H; Ren M; Savage NM; Chang CS; Cowell JK
Cancer Res; 2019 Jan; 79(1):114-124. PubMed ID: 30413411
[TBL] [Abstract][Full Text] [Related]
11. FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
Hu T; Wu Q; Chong Y; Qin H; Poole CJ; van Riggelen J; Ren M; Cowell JK
Leukemia; 2018 Nov; 32(11):2363-2373. PubMed ID: 29720732
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation.
Peiris MN; Meyer AN; Nelson KN; Bisom-Rapp EW; Donoghue DJ
Haematologica; 2020 May; 105(5):1262-1273. PubMed ID: 31439673
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of two rare BCR-FGFR1
Barnes EJ; Leonard J; Medeiros BC; Druker BJ; Tognon CE
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 31980503
[TBL] [Abstract][Full Text] [Related]
14. The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).
Wasag B; Lierman E; Meeus P; Cools J; Vandenberghe P
Haematologica; 2011 Jun; 96(6):922-6. PubMed ID: 21330321
[TBL] [Abstract][Full Text] [Related]
15. The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase.
Hu T; Chong Y; Qin H; Kitamura E; Chang CS; Silva J; Ren M; Cowell JK
Oncogene; 2018 Apr; 37(14):1926-1938. PubMed ID: 29367757
[TBL] [Abstract][Full Text] [Related]
16. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.
Demiroglu A; Steer EJ; Heath C; Taylor K; Bentley M; Allen SL; Koduru P; Brody JP; Hawson G; Rodwell R; Doody ML; Carnicero F; Reiter A; Goldman JM; Melo JV; Cross NC
Blood; 2001 Dec; 98(13):3778-83. PubMed ID: 11739186
[TBL] [Abstract][Full Text] [Related]
17. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.
Cowell JK; Qin H; Hu T; Wu Q; Bhole A; Ren M
Int J Cancer; 2017 Nov; 141(9):1822-1829. PubMed ID: 28646488
[TBL] [Abstract][Full Text] [Related]
18. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.
Chase A; Grand FH; Cross NC
Blood; 2007 Nov; 110(10):3729-34. PubMed ID: 17698633
[TBL] [Abstract][Full Text] [Related]
19. Src kinase modulates the activation, transport and signalling dynamics of fibroblast growth factor receptors.
Sandilands E; Akbarzadeh S; Vecchione A; McEwan DG; Frame MC; Heath JK
EMBO Rep; 2007 Dec; 8(12):1162-9. PubMed ID: 17975556
[TBL] [Abstract][Full Text] [Related]
20. Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.
Heath C; Cross NC
J Biol Chem; 2004 Feb; 279(8):6666-73. PubMed ID: 14660670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
